LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 78.98 | 770.25 | 12244 | 11518 | 1.0630 | 1.0316 | MN20160304_L02 | N15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 81.20 | 770.25 | 13090 | 11766 | 1.1125 | 1.0549 | MN20160304_L02 | L17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 81.20 | 770.25 | 12464 | 11766 | 1.0593 | 1.0295 | MN20160304_L02 | N15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 83.42 | 770.25 | 13595 | 12031 | 1.1299 | 1.0626 | MN20160304_L02 | L17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 83.42 | 770.25 | 12883 | 12031 | 1.0707 | 1.0348 | MN20160304_L02 | N15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 85.64 | 770.25 | 13878 | 12287 | 1.1295 | 1.0619 | MN20160304_L02 | L17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 85.64 | 770.25 | 13233 | 12287 | 1.0770 | 1.0375 | MN20160304_L02 | N15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 87.86 | 770.25 | 14304 | 12543 | 1.1404 | 1.0663 | MN20160304_L02 | L17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0010833 | 87.86 | 770.25 | 13544 | 12543 | 1.0798 | 1.0385 | MN20160304_L02 | N15 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 3.21 | 770.25 | 768 | 904 | 0.8490 | -0.0125 | MN20160304_L02 | H11 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 3.21 | 770.25 | 965 | 904 | 1.0667 | 1.6423 | MN20160304_L02 | K13 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 5.44 | 770.25 | 864 | 1012 | 0.8531 | 0.3376 | MN20160304_L02 | H11 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 5.44 | 770.25 | 1067 | 1012 | 1.0536 | 1.2825 | MN20160304_L02 | K13 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 7.66 | 770.25 | 931 | 1090 | 0.8541 | 0.4599 | MN20160304_L02 | H11 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 7.66 | 770.25 | 1111 | 1090 | 1.0193 | 1.0777 | MN20160304_L02 | K13 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 10.06 | 770.25 | 1055 | 1218 | 0.8658 | 0.6087 | MN20160304_L02 | H11 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 10.06 | 770.25 | 1201 | 1218 | 0.9856 | 0.9568 | MN20160304_L02 | K13 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 12.28 | 770.25 | 1193 | 1358 | 0.8784 | 0.7070 | MN20160304_L02 | H11 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 12.28 | 770.25 | 1386 | 1358 | 1.0205 | 1.0503 | MN20160304_L02 | K13 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 14.50 | 770.25 | 1305 | 1497 | 0.8716 | 0.7330 | MN20160304_L02 | H11 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 14.50 | 770.25 | 1561 | 1497 | 1.0426 | 1.0889 | MN20160304_L02 | K13 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 16.73 | 770.25 | 1440 | 1664 | 0.8651 | 0.7556 | MN20160304_L02 | H11 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 16.73 | 770.25 | 1722 | 1664 | 1.0345 | 1.0620 | MN20160304_L02 | K13 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 18.95 | 770.25 | 1626 | 1832 | 0.8873 | 0.8176 | MN20160304_L02 | H11 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.0033333 | 18.95 | 770.25 | 1861 | 1832 | 1.0156 | 1.0248 | MN20160304_L02 | K13 |